C12N 2502/1114
T cells
C12N2502/1114 (T cells) appears on 131 US grants and 300 published applications in this corpus.
Search patents in C12N- Granted patents
- 131
- Published applications
- 300
- Assignees
- 201
- Inventors
- 557
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 3 |
| 2006 | 0 | 3 |
| 2007 | 0 | 3 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 4 | 4 |
| 2011 | 5 | 6 |
| 2012 | 3 | 3 |
| 2013 | 1 | 4 |
| 2014 | 6 | 9 |
| 2015 | 4 | 11 |
| 2016 | 5 | 7 |
| 2017 | 6 | 14 |
| 2018 | 8 | 14 |
| 2019 | 7 | 22 |
| 2020 | 5 | 21 |
| 2021 | 9 | 41 |
| 2022 | 11 | 32 |
| 2023 | 10 | 22 |
| 2024 | 22 | 35 |
| 2025 | 13 | 25 |
| 2026 | 10 | 16 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells7 Jul 2026US 12,674,138 B2NKMAX Co., Ltd.
- Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy30 Jun 2026US 12,668,776 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Materials and methods for the manufacture of pluripotent stem cells30 Jun 2026US 12,668,781 B2Janssen Biotech, Inc.
- Methods for treating an immune disorder-related disease by reducing autoreactivity in a T cell compartment9 Jun 2026US 12,649,905 B2Hackensack University Medical Center
- Production of a bioengineered lung28 Apr 2026US 12,612,602 B2Board of Regents, The University of Texas System
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
- Method for culturing cord blood-derived natural killer cells using transformed t-cells1 Oct 2026US 2026/0297526 A1GC Cell Corporation
- Cancer models1 Oct 2026US 2026/0297534 A1Carcinotech Ltd
- Single b-cell cultivation method24 Sep 2026US 2026/0285949 A1Hoffmann-La Roche Inc.
- Materials and methods for the manufacture of pluripotent stem cells17 Sep 2026US 2026/0275300 A1Janssen Biotech, Inc.
Most cited
By later US patents
- Artificial antigen presenting cells and uses therefor105US 7,754,482 B2The Trustees of the University of Pennsylvania · 2010
- Artificial antigen presenting cells and uses therefor76US 8,722,400 B2The Trustees of the University of Pennsylvania · 2014
- Three dimensional vaginal tissue model containing immune cells53US 6,943,021 B2MatTek Corporation · 2005
- Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation46US 8,617,884 B2Life Technologies Corporation · 2013
- Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation44US 9,528,088 B2Life Technologies Corporation · 2016